Best Peptide for Gastric Mucosal Protection Research
BPC-157 is the undisputed leader for gastric mucosal protection and cytoprotective pathway research. Originally isolated from human gastric juice, this pentadecapeptide maintains its native biological context and demonstrates the most extensive published data in gastric injury models.
TOP RECOMMENDATION
BPC-157 — Body Protection Compound-157
BPC-157 is the definitive and essentially sole peptide choice for gastric mucosal protection research. Its origin — isolation from human gastric juice — provides a unique biological relevance unmatched by any other peptide in the catalog. BPC-157 stabilizes the gastric mucosal barrier through nitric oxide synthesis enhancement, maintains cytoprotective pathways independent of prostaglandins, and demonstrates efficacy across ethanol, NSAID, restraint-stress, and ischemia-reperfusion gastric injury models. TB-500 offers no meaningful gastric protection mechanism; its actin regulation and systemic anti-inflammatory signaling do not address gastric epithelial barrier function. For gastric ulcer, gastritis, and cytoprotective pathway research, BPC-157 stands alone as the established standard with over 50 peer-reviewed publications in gastric models.
WHY IT WINS
- Originally isolated from human gastric juice — its native biological context is gastric mucosal cytoprotection
- Stabilizes the gastric mucosal barrier through nitric oxide-mediated vasodilation and prostaglandin-independent cytoprotection
- Demonstrates the most extensive peer-reviewed publication record in gastric ulcer, gastritis, and NSAID-induced injury models
- Protects against ethanol, indomethacin, and restraint-stress induced gastric lesions in established animal models
- Maintains the gut-brain axis and cytoprotective pathways without the side-effect profiles of proton pump inhibitors or H2 antagonists
APPLICATION SUITABILITY MATRIX
| RESEARCH APPLICATION | BPC-157 | ALTERNATIVE |
|---|---|---|
| Gastric Mucosal Barrier | ||
| Ethanol-Induced Lesion Protection | ||
| NSAID Gastropathy Models | ||
| Gut-Brain Axis Modulation | ||
| Cytoprotective NO Signaling | ||
| Enteric Nervous System | ||
| General Anti-Inflammatory | ||
| Cost & Stability |
IDEAL RESEARCH APPLICATIONS
- Ethanol and NSAID-induced gastric lesion models
- Gastric mucosal barrier function assays
- Gastric epithelial cell cytoprotection studies
- Restraint stress and ischemia-reperfusion gastric injury
- Gut-brain axis and enteric nervous system research
NO CLOSE ALTERNATIVE
BPC-157 stands alone in this category.
No other peptide in the Ares Research catalog offers a mechanism specifically relevant to gastric protection. While broader comparisons exist with TB-500 for general tissue repair, the gastric protection mechanism of BPC-157 is unique among our compounds.
ANALYTICAL SPECIFICATIONS
Compound
Body Protection Compound-157
CAS Number
137525-51-0
Purity (HPLC)
≥ 99.2%
Molecular Weight
1,419.5 g/mol
Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Verification
HPLC + MS per batch
FREQUENTLY ASKED QUESTIONS
Why is BPC-157 the only peptide for gastric protection research?
BPC-157 was originally isolated from human gastric juice, giving it a unique biological relevance to gastric mucosal cytoprotection. Its mechanism — nitric oxide synthesis enhancement, prostaglandin-independent cytoprotection, and gut-brain axis stabilization — is specific to gastric epithelial barrier function. No other peptide in the catalog offers this targeted gastric mechanism.
What concentration of BPC-157 is used in gastric cell culture?
For gastric epithelial cell lines (AGS, MKN-28) or primary gastric mucosal cells, BPC-157 is typically evaluated at 1–10 mcg/ml in complete media. Cytoprotection against ethanol or indomethacin challenge is assessed by cell viability (MTT), LDH release, and tight junction protein expression (ZO-1, occludin) at 24–48 hours.
Does BPC-157 protect against NSAID-induced gastric injury?
Yes. BPC-157 has been extensively studied in indomethacin, diclofenac, and aspirin-induced gastric injury models. Its cytoprotective mechanism operates independently of prostaglandins, distinguishing it from conventional gastroprotective agents.
Is BPC-157 effective in ischemia-reperfusion gastric injury?
Yes. BPC-157 demonstrates protective effects in gastric ischemia-reperfusion models through nitric oxide-mediated vasodilation and anti-oxidant enzyme upregulation. These cytoprotective effects are observed in both in-vivo and ex-vivo gastric models.
Can BPC-157 be combined with proton pump inhibitors in gastric studies?
Yes. Many researchers evaluate BPC-157 alongside or in comparison with omeprazole, ranitidine, or misoprostol as positive controls. BPC-157 operates through a distinct mechanism (NO synthesis, prostaglandin-independent) and can be studied in combination or as a comparative agent.
REFERENCES
- [1]Sikiric, P. et al. (2016). The pharmacological properties of the peptide BPC 157. Current Pharmaceutical Design, 22(32), 4966–4973.
- [2]Stupnisek, M. et al. (2015). BPC 157 as a prototype cytoprotective mediator. Journal of Physiology-Paris, 109(1–3), 119–129.
- [3]Seiwerth, S. et al. (2014). BPC 157 effect on healing. World Journal of Gastroenterology, 20(27), 8997–9005.
- [4]Chang, C.H. et al. (2011). Pentadecapeptide BPC 157 enhances the growth hormone receptor. Journal of Physiology-Paris, 105(2–3), 120–131.
TOP RECOMMENDATION
BPC-157
Body Protection Compound-157
QUICK LINKS
RELATED RESEARCH GOALS
RESEARCH USE ONLY. All compounds are strictly for in-vitro laboratory research by qualified professionals. Not for human consumption, veterinary use, or clinical application.